Ulinastatin in the treatment of severe acute pancreatitis: A single-center randomized controlled trial

Abstract

BACKGROUND Severe acute pancreatitis (AP) is one of the most common diseases of the gastrointestinal tract and carries a significant financial burden with high disability and mortality. There are no effective drugs in the clinical management of severe AP, and there is an absence of evidence-based medicine concerning the treatment of severe AP. AIM To explore whether ulinastatin (UTI) can improve the outcome of severe AP. METHODS The present research included patients who were hospitalized in intensive critical care units (ICUs) after being diagnosed with severe AP. Patients received UTI (400000 IU) or placebos utilizing computer-based random sequencing (in a 1:1 ratio). The primary outcome measures were 7-d mortality, clinical efficacy, inflammatory response, coagulation function, infection, liver function, renal function, and drug-related adverse effects were evaluated. RESULTS A total of 181 individuals were classified into two groups, namely, the placebo group ( n = 90) and the UTI group ( n = 91). There were no statistically significant differences in baseline clinical data between the two groups. The 7-d mortality and clinical efficacy in the UTI group were remarkably improved compared with those in the placebo group. UTI can protect against hyperinflammation and improve coagulation dysfunction, infection, liver function, and renal function. UTI patients had markedly decreased hospital stays and hospitalization expenditures compared with the placebo group. CONCLUSION The findings from the present research indicated that UTI can improve the clinical outcomes of patients with severe AP and has fewer adverse reactions.

The impact of ulinastatin on wound infection and healing in patients with burn wounds: A meta‐analysis

“…Ulinastatin has a protective effect against sepsis-induced multiorgan damage, inhibiting oxidative-induced hyperpermeability in human endothelial cells and decreasing the levels of the cytokines tumour necrosis factor-α and interleukin-6 in damaged organs. 7,21 Chen et al 22 found that, in healthy adults, high-dose ulinastatin was well tolerated up to a maximum dose of 8 million units. Basic science and clinical research studies have shown that ulinastatin can inhibit the activity of various proteases, downregulate the formation of inflammatory factors and excessive superoxide, and scavenge oxygenfree radicals, thereby protecting the heart, lungs, brain, liver, kidneys, and other organs, as well as improving immune function and coagulation.…”